Eesti - eesti - Ravimiamet

cipla europe nv - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 6tk; 50mcg 1ml 2.5ml 3tk; 50mcg 1ml 2.5ml 1tk

Eesti - eesti - Ravimiamet

cipla europe nv - paratsetamool - kihisev tablett - 1000mg 20tk; 1000mg 100tk; 1000mg 8tk

Eesti - eesti - Ravimiamet

cipla europe nv - paratsetamool - kihisev tablett - 500mg 32tk; 500mg 60tk

Eesti - eesti - Ravimiamet

cipla (eu) limited - mometasoon - ninasprei, suspensioon - 50mcg 1annus 140annus 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

cipla (eu) limited - olansapiin - schizophrenia; bipolar disorder - psühhoeptikumid - adultsolanzapine on näidustatud skisofreenia ravi. olansapiin on efektiivne, säilitades kliinilist paranemist ajal jätkamine ravi patsientidel, kes on näidanud, esialgne ravi vastuseks. olansapiin on näidustatud ravi mõõduka kuni raske maniakaalse episoodi. patsientidel, kelle maniakaalne episood on vastanud, et olansapiin-ravi, olansapiin on näidustatud kordumise ennetamiseks patsientidel, kellel on bipolaarne häire.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mabxience research sl - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Eesti - eesti - Ravimiamet

cipla limited - sennaglükosiidid - tablett - 20tk

Eesti - eesti - Ravimiamet

exeltis baltics uab - tamsulosiin+dutasteriid - kõvakapsel - 0,4mg+0,5mg 90tk; 0,4mg+0,5mg 30tk; 0,4mg+0,5mg 7tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - oksaliplatiin - infusioonilahuse kontsentraat - 5mg 1ml 20ml 1tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - oksaliplatiin - infusioonilahuse kontsentraat - 5mg 1ml 10ml 1tk